Drugs / MB-CART20.1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03893019 | Mar 2019 → Jan 2023 | cutaneous melanoma | Miltenyi Biomedicine GmbH | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03664635 | Sep 2018 → Sep 2024 | B-cell non-Hodgkin lymphoma | Miltenyi Biomedicine GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT02737085 | Mar 2016 → Dec 2019 | diffuse large B-cell lymphoma | Southwest Hospital, China | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06508775 | May 2024 → Dec 2040 expected | childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, melanoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-CART20.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893019 ↗ |
| Known as | Anti-CD20 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02737085 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T(CAR-T) cells” NCT02737085 ↗ |
| Route | Intravenous | “administered intravenously” NCT03664635 ↗ |